Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA user fee plan

This article was originally published in The Tan Sheet

Executive Summary

Agency is authorized to collect $740 mil. in fees over five years, with $456 mil. of that to be used to maintain improvements, such as faster review times, wrought by the first Prescription Drug User Fee Act and to sustain 659 staff-years of program each year that made those improvements possible, according to the FDA PDUFA II five-year plan, whose availability FDA announced July 10. The remaining $284 mil. will be invested to enable FDA to meet the new PDUFA II goals, the agency says. CDER will receive 56% of the total. Of the overall monies, 58% will go for pay and benefits for additional agency staff (983 more staff-years, i.e., 325 more FTEs in 2002 than in the drug evaluation process in 1992) and 13% for information technology...

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS088643

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel